Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.

MLA

Frange, Pierre, et al. “Lopinavir/Ritonavir-Based Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Naive Children: Rare Protease Inhibitor Resistance Mutations but High Lamivudine/Emtricitabine Resistance at the Time of Virologic Failure.” The Pediatric Infectious Disease Journal, vol. 30, no. 8, Aug. 2011, pp. 684–88. EBSCOhost, https://doi.org/10.1097/INF.0b013e31821752d6.

APA

Frange, P., Briand, N., Avettand-fenoel, V., Veber, F., Moshous, D., Mahlaoui, N., Rouzioux, C., Blanche, S., & Chaix, M.-L. (2011). Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure. The Pediatric Infectious Disease Journal, 30(8), 684–688. https://doi.org/10.1097/INF.0b013e31821752d6

Chicago

Frange, Pierre, Nelly Briand, Véronique Avettand-fenoel, Florence Veber, Despina Moshous, Nizar Mahlaoui, Christine Rouzioux, Stéphane Blanche, and Marie-Laure Chaix. 2011. “Lopinavir/Ritonavir-Based Antiretroviral Therapy in Human Immunodeficiency Virus Type 1-Infected Naive Children: Rare Protease Inhibitor Resistance Mutations but High Lamivudine/Emtricitabine Resistance at the Time of Virologic Failure.” The Pediatric Infectious Disease Journal 30 (8): 684–88. doi:10.1097/INF.0b013e31821752d6.